Recruiting
Colorectal cancer metastatic
RecruitingINCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Registered drug
INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Registered drug
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+3
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Bevacizumab



